Chrono Therapeutics Gets $32M For Smoking Cessation

Hayward-based Chrono Therapeutics, which is developing products to help patients with quitting smoking, said Thursday that it has raised $32M in a Series A funding round. The funding came from Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, Mayo Clinic and GE Ventures. The firm is developing a programmable transdermal drug delivery system for smoking cessation efforts. Wende Hutton of Canaan Partners, Jim Young of 5AM Ventures, and Aiden King of Fountain join the company's board with the funding. Chrono Therapeutics is led by Alan Levy.